<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">mrj</journal-id><journal-title-group><journal-title xml:lang="ru">Современная ревматология</journal-title><trans-title-group xml:lang="en"><trans-title>Modern Rheumatology Journal</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1996-7012</issn><issn pub-type="epub">2310-158X</issn><publisher><publisher-name>IMA-PRESS, LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14412/1996-7012-2025-2-50-57</article-id><article-id custom-type="elpub" pub-id-type="custom">mrj-1739</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL INVESTIGATIONS</subject></subj-group></article-categories><title-group><article-title>Коморбидные инфекции у пациентов с АНЦА-ассоциированными системными васкулитами: проспективное когортное исследование</article-title><trans-title-group xml:lang="en"><trans-title>Comorbid infections in patients with ANCA-associated systemic vasculitis: a prospective cohort study</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3136-2755</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Литвинова</surname><given-names>М. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Litvinova</surname><given-names>M. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>119021, Москва, ул. Россолимо, 11, стр. 5</p></bio><bio xml:lang="en"><p>11, Rossolimo Street, Build. 5, Moscow 119021</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3989-2590</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Буланов</surname><given-names>Н. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Bulanov</surname><given-names>N. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Николай Михайлович Буланов</p><p>119021, Москва, ул. Россолимо, 11, стр. 5</p></bio><bio xml:lang="en"><p>Nikolay Mikhailovich Bulanov</p><p>11, Rossolimo Street, Build. 5, Moscow 119021</p></bio><email xlink:type="simple">bulanov_n_m@staff.sechenov.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0148-5655</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Новиков</surname><given-names>П. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Novikov</surname><given-names>P. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>119021, Москва, ул. Россолимо, 11, стр. 5</p></bio><bio xml:lang="en"><p>11, Rossolimo Street, Build. 5, Moscow 119021</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2275-9865</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Чжао</surname><given-names>Ц.</given-names></name><name name-style="western" xml:lang="en"><surname>Zhao</surname><given-names>J.</given-names></name></name-alternatives><bio xml:lang="ru"><p>119021, Москва, ул. Россолимо, 11, стр. 5</p></bio><bio xml:lang="en"><p>11, Rossolimo Street, Build. 5, Moscow 119021</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9652-6856</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Мунблит</surname><given-names>Д. Б.</given-names></name><name name-style="western" xml:lang="en"><surname>Munblit</surname><given-names>D.</given-names></name></name-alternatives><bio xml:lang="ru"><p>123337, Москва, Шмитовский проезд, 29</p><p>Стрэнд, Лондон WC2R 2LS, Великобритания</p></bio><bio xml:lang="en"><p>29. Shmitovskiy Proezd, Moscow 123337</p><p>Strand, London WC2R 2LS</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7232-4640</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Моисеев С.В</surname><given-names>С. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Moiseev</surname><given-names>S. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>119021, Москва, ул. Россолимо, 11, стр. 5</p></bio><bio xml:lang="en"><p>11, Rossolimo Street, Build. 5, Moscow 119021</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Клиника ревматологии, нефрологии и профпатологии им. Е.М. Тареева</institution><country>Россия</country></aff><aff xml:lang="en"><institution>E.M. Tareev Clinic of Rheumatology, Nephrology and Occupational Diseases</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Кафедра педиатрии и детских инфекционных болезней ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет); Королевский колледж Лондона</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Department of Paediatrics and Paediatric Infectious Diseases, I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University); King’s College London</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>22</day><month>04</month><year>2025</year></pub-date><volume>19</volume><issue>2</issue><fpage>50</fpage><lpage>57</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Литвинова М.А., Буланов Н.М., Новиков П.И., Чжао Ц., Мунблит Д.Б., Моисеев С.В С.В., 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="ru">Литвинова М.А., Буланов Н.М., Новиков П.И., Чжао Ц., Мунблит Д.Б., Моисеев С.В С.В.</copyright-holder><copyright-holder xml:lang="en">Litvinova M.A., Bulanov N.M., Novikov P.I., Zhao J., Munblit D., Moiseev S.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://mrj.ima-press.net/mrj/article/view/1739">https://mrj.ima-press.net/mrj/article/view/1739</self-uri><abstract><p>Современные методы лечения существенно улучшили выживаемость при ассоциированных с антинейтрофильными цитоплазматическими антителами системных васкулитах (АНЦА-СВ), однако они связаны с повышенным риском инфекций, которые являются одной из ведущих причин госпитализации и смерти таких больных.</p><p>Цель исследования – изучение частоты, структуры и факторов риска коморбидных инфекций у пациентов с АНЦА-СВ.</p><sec><title>Материал и методы</title><p>Материал и методы. В проспективное когортное исследование включено 130 пациентов с АНЦА-СВ старше 18 лет, в том числе 87 – с гранулематозом с полиангиитом, 32 – с микроскопическим полиангиитом и 11 – с эозинофильным гранулематозом с полиангиитом. На этапе включения анализировали первичную медицинскую документацию, рассчитывали индексы BVAS и VDI. Динамическое наблюдение осуществляли ежемесячно на протяжении 12 мес. Первичной конечной точкой в исследовании был эпизод инфекции, зарегистрированный при очередном контакте с пациентом, вторичными конечными точками – тяжелые инфекции.</p></sec><sec><title>Результаты и обсуждение</title><p>Результаты и обсуждение. За 12 мес наблюдения у 130 пациентов с АНЦА-СВ был выявлен 281 эпизод различных инфекций (238 эпизодов на 100 пациенто-лет, 95% доверительный интервал, ДИ 209–270), чаще всего встречались инфекции верхних дыхательных путей. Как тяжелые расценены 23 случая инфекций у 14 больных (19,5 эпизода на 100 пациенто-лет, 95% ДИ 12,2–30,9), в 3 случаях зафиксирован связанный с инфекцией летальный исход.</p></sec><sec><title>Заключение</title><p>Заключение. Результаты исследования показали, что у пациентов с АНЦА-СВ регистрируется высокая частота инфекций, в том числе тяжелых, которые являются у них фактором неблагоприятного исхода.</p></sec></abstract><trans-abstract xml:lang="en"><p>State-of-the-art management of ANCA-associated vasculitis (AAV) has significantly improved patient survival, but is associated with an increased risk of infectious complications, that currently are one of the leading causes of hospitalization and mortality in patients with AAV.</p><sec><title>Objective</title><p>Objective: to assess the incidence and structure of comorbid infections in patients with AAV.</p></sec><sec><title>Material and methods</title><p>Material and methods. In this prospective cohort study, we enrolled 130 patients over 18 years of age diagnosed with AAV, including 87 patients with granulomatosis with polyangiitis, 32 with microscopic polyangiitis and 11 with eosinophilic granulomatosis with polyangiitis. In all patients primary medical records were analyzed, BVAS and VDI indices were calculated. Dynamic follow-up was performed monthly for 12 months. The primary endpoint in the study was an episode of infection registered at the next contact with the patient, secondary endpoints were severe infections.</p></sec><sec><title>Results and discussion</title><p>Results and discussion. During the 12 months of follow-up in 130 patients 281 cases of various infectious diseases were reported (238 episodes of infections per 100 patient-years, 95% CI 209–270), with patients most commonly reporting episodes of upper respiratory tract infections. Among all infections, there were 23 cases (19.5 episodes per 100 patient-years, 95% CI 12.2–30.9) of severe infections in 14 patients and 3 deaths due to infectious complications.</p></sec><sec><title>Conclusions</title><p>Conclusions. The results of our study demonstrate a high incidence of infectious diseases including severe infections in patients with AAV and emphasize the relevance of infectious complications as a factor associated with adverse outcomes in patients with AAV.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>АНЦА-ассоциированные васкулиты</kwd><kwd>иммуносупрессивная терапия</kwd><kwd>инфекции</kwd><kwd>сепсис</kwd></kwd-group><kwd-group xml:lang="en"><kwd>ANCA-associated vasculitis</kwd><kwd>immunosuppressive therapy</kwd><kwd>infections</kwd><kwd>sepsis</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013 Jan;65(1):1-11. doi: 10.1002/art.37715.</mixed-citation><mixed-citation xml:lang="en">Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013 Jan;65(1):1-11. doi: 10.1002/art.37715.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Новиков ПИ, Семенкова ЕН, Моисе ев СВ. Современная номенклатура системных васкулитов. Клиническая фармакология и терапия. 2013;22(1):70-4.</mixed-citation><mixed-citation xml:lang="en">Novikov PO, Semenkova EN, Moiseev SV. Modern nomenclature of systemic vasculitis. Klinicheskaya farmakologiya i terapiya. 2013; 22(1):70-4. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Little MA, Nightingale P, Verburgh CA, et al. Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis. Ann Rheum Dis. 2010 Jun;69(6): 1036-43. doi: 10.1136/ard.2009.109389. Epub 2009 Jul 1.</mixed-citation><mixed-citation xml:lang="en">Little MA, Nightingale P, Verburgh CA, et al. Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis. Ann Rheum Dis. 2010 Jun;69(6): 1036-43. doi: 10.1136/ard.2009.109389. Epub 2009 Jul 1.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Flossmann O, Berden A, de Groot K, et al. Long-term patient survival in ANCA-associated vasculitis. Ann Rheum Dis. 2011 Mar; 70(3):488-94. doi: 10.1136/ard.2010.137778. Epub 2010 Nov 24.</mixed-citation><mixed-citation xml:lang="en">Flossmann O, Berden A, de Groot K, et al. Long-term patient survival in ANCA-associated vasculitis. Ann Rheum Dis. 2011 Mar; 70(3):488-94. doi: 10.1136/ard.2010.137778. Epub 2010 Nov 24.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Singer M, Deutschman CS, Seymour CW, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016 Feb 23;315(8):801-10. doi: 10.1001/jama.2016.0287.</mixed-citation><mixed-citation xml:lang="en">Singer M, Deutschman CS, Seymour CW, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016 Feb 23;315(8):801-10. doi: 10.1001/jama.2016.0287.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Gialouri CG, Chalkia A, Koutsianas C, et al. Relapses and serious adverse events during rituximab maintenance therapy in ANCA-associated vasculitis: a multicentre retrospective study. Rheumatology (Oxford). 2024 Aug 6:keae409. doi: 10.1093/rheumatology/keae409. Online ahead of print.</mixed-citation><mixed-citation xml:lang="en">Gialouri CG, Chalkia A, Koutsianas C, et al. Relapses and serious adverse events during rituximab maintenance therapy in ANCA-associated vasculitis: a multicentre retrospective study. Rheumatology (Oxford). 2024 Aug 6:keae409. doi: 10.1093/rheumatology/keae409. Online ahead of print.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Thomas K, Argyriou E, Kapsala N, et al. Serious infections in ANCA-associated vasculitides in the biologic era: real-life data from a multicenter cohort of 162 patients. Arthritis Res Ther. 2021 Mar 20;23(1):90. doi: 10.1186/s13075-021-02452-8.</mixed-citation><mixed-citation xml:lang="en">Thomas K, Argyriou E, Kapsala N, et al. Serious infections in ANCA-associated vasculitides in the biologic era: real-life data from a multicenter cohort of 162 patients. Arthritis Res Ther. 2021 Mar 20;23(1):90. doi: 10.1186/s13075-021-02452-8.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Weidanz F, Day CJ, Hewins P, et al. Recurrences and infections during continuous immunosuppressive therapy after beginning dialysis in ANCA-associated vasculitis. Am J Kidney Dis. 2007 Jul;50(1):36-46. doi: 10.1053/j.ajkd.2007.04.018.</mixed-citation><mixed-citation xml:lang="en">Weidanz F, Day CJ, Hewins P, et al. Recurrences and infections during continuous immunosuppressive therapy after beginning dialysis in ANCA-associated vasculitis. Am J Kidney Dis. 2007 Jul;50(1):36-46. doi: 10.1053/j.ajkd.2007.04.018.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Rathmann J, Jayne D, Segelmark M, et al. Incidence and predictors of severe infections in ANCA-associated vasculitis: a populationbased cohort study. Rheumatology (Oxford). 2021 Jun 18;60(6):2745-2754. doi: 10.1093/rheumatology/keaa699.</mixed-citation><mixed-citation xml:lang="en">Rathmann J, Jayne D, Segelmark M, et al. Incidence and predictors of severe infections in ANCA-associated vasculitis: a populationbased cohort study. Rheumatology (Oxford). 2021 Jun 18;60(6):2745-2754. doi: 10.1093/rheumatology/keaa699.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Thery-Casari C, Euvrard R, Mainbourg S, et al. Severe infections in patients with antineutrophil cytoplasmic antibody-associated vasculitides receiving rituximab: A metaanalysis. Autoimmun Rev. 2020 May;19(5): 102505. doi: 10.1016/j.autrev.2020.102505. Epub 2020 Mar 12.</mixed-citation><mixed-citation xml:lang="en">Thery-Casari C, Euvrard R, Mainbourg S, et al. Severe infections in patients with antineutrophil cytoplasmic antibody-associated vasculitides receiving rituximab: A metaanalysis. Autoimmun Rev. 2020 May;19(5): 102505. doi: 10.1016/j.autrev.2020.102505. Epub 2020 Mar 12.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Obrisca B, Vornicu A, Jurubita R, et al. Corticosteroids are the major contributors to the risk for serious infections in autoimmune disorders with severe renal involvement. Clin Rheumatol. 2021 Aug;40(8):3285-3297. doi: 10.1007/s10067-021-05646-2. Epub 2021 Feb 17.</mixed-citation><mixed-citation xml:lang="en">Obrisca B, Vornicu A, Jurubita R, et al. Corticosteroids are the major contributors to the risk for serious infections in autoimmune disorders with severe renal involvement. Clin Rheumatol. 2021 Aug;40(8):3285-3297. doi: 10.1007/s10067-021-05646-2. Epub 2021 Feb 17.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Furer V, Rondaan C, Heijstek MW, et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2020 Jan;79(1):39-52. doi: 10.1136/annrheumdis-2019-215882. Epub 2019 Aug 14.</mixed-citation><mixed-citation xml:lang="en">Furer V, Rondaan C, Heijstek MW, et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2020 Jan;79(1):39-52. doi: 10.1136/annrheumdis-2019-215882. Epub 2019 Aug 14.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Landewe RBM, Kroon FPB, Alunno A, et al. EULAR recommendations for the management and vaccination of people with rheumatic and musculoskeletal diseases in the context of SARS-CoV-2: the November 2021 update. Ann Rheum Dis. 2022 Dec;81(12): 1628-1639. doi: 10.1136/annrheumdis-2021-222006. Epub 2022 Feb 23.</mixed-citation><mixed-citation xml:lang="en">Landewe RBM, Kroon FPB, Alunno A, et al. EULAR recommendations for the management and vaccination of people with rheumatic and musculoskeletal diseases in the context of SARS-CoV-2: the November 2021 update. Ann Rheum Dis. 2022 Dec;81(12): 1628-1639. doi: 10.1136/annrheumdis-2021-222006. Epub 2022 Feb 23.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Буланов НМ, Новиков ПИ, Гуляев СВ и др. Переносимость вакцины Гам-КОВИД-Вак (Спутник V) у взрослых пациентов с иммуновоспалительными ревматическими заболеваниями. Клиническая фармакология и терапия. 2021; 30(4):23-28.</mixed-citation><mixed-citation xml:lang="en">Bulanov NM, Novikov PI, Gulyaev SV, et al. Tolerability and safety of Gam-COVID-Vac (Sputnik V) vaccine in adult patients with autoimmune rheumatic diseases. Klinicheskaya farmakologiya i terapiya. 2021;30(4): 23-28. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Литвинова МА, Буланов НМ, Нови ков ПИ и др. Применение тиксагевимаба и цилгавимаба (Эвушелд) для доконтактной профилактики COVID-19 у пациентов с АНЦА-ассоциированными васкулитами: проспективное исследование. Клиническая фармакология и терапия. 2023;32(4): 24-29.</mixed-citation><mixed-citation xml:lang="en">Litvinova MA, Bulanov NM, Novikov PI, et al. Tixagevimab/cilgavimab (Evusheld) for pre-exposure prophylaxis of COVID-19 in patients with ANCA-associated vasculitis: a prospective study. Klinicheskaya farmakologiya i terapiya. 2023;32(4):24-29. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Белов БС, Тарасова ГМ, Буханова ДВ. Коморбидные инфекции при ревматических заболеваниях. Антибиотики и химиотерапия. 2019;64(1-2):50-57.</mixed-citation><mixed-citation xml:lang="en">Belov BS, Tarasova GM, Bukhanova DV. Comorbid infections in rheumatic diseases. Antibiotiki i khimioterapiya. 2019;64(1-2):50-57. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Smith R. Complications of therapy for ANCA-associated vasculitis. Rheumatology (Oxford). 2020 May 1;59(Suppl 3):iii74-iii78. doi: 10.1093/rheumatology/kez618. PMID: 31967652.</mixed-citation><mixed-citation xml:lang="en">Smith R. Complications of therapy for ANCA-associated vasculitis. Rheumatology (Oxford). 2020 May 1;59(Suppl 3):iii74-iii78. doi: 10.1093/rheumatology/kez618. PMID: 31967652.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Booth AD, Almond MK, Burns A, et al. Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study. Am J Kidney Dis. 2003 Apr;41(4):776-84. doi: 10.1016/s0272-6386(03)00025-8.</mixed-citation><mixed-citation xml:lang="en">Booth AD, Almond MK, Burns A, et al. Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study. Am J Kidney Dis. 2003 Apr;41(4):776-84. doi: 10.1016/s0272-6386(03)00025-8.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Yang L, Xie H, Liu Z, et al. Risk factors for infectious complications of ANCA-associated vasculitis: a cohort study. BMC Nephrol. 2018 Jun 14;19(1):138. doi: 10.1186/s12882-018-0933-2.</mixed-citation><mixed-citation xml:lang="en">Yang L, Xie H, Liu Z, et al. Risk factors for infectious complications of ANCA-associated vasculitis: a cohort study. BMC Nephrol. 2018 Jun 14;19(1):138. doi: 10.1186/s12882-018-0933-2.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Goupil R, Brachemi S, Nadeau-Fredet te AC, et al. Lymphopenia and treatment-related infectious complications in ANCA-associated vasculitis. Clin J Am Soc Nephrol. 2013 Mar;8(3):416-23. doi: 10.2215/CJN.07300712. Epub 2012 Dec 6.</mixed-citation><mixed-citation xml:lang="en">Goupil R, Brachemi S, Nadeau-Fredet te AC, et al. Lymphopenia and treatment-related infectious complications in ANCA-associated vasculitis. Clin J Am Soc Nephrol. 2013 Mar;8(3):416-23. doi: 10.2215/CJN.07300712. Epub 2012 Dec 6.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Nettleton E, Sattui SE, Wallace Z, Putman M. Incidence of Pneumocystis Jiroveci Pneumonia in Patients With ANCA-Associated Vasculitis Initiating Therapy With Rituximab or Cyclophosphamide. Arthritis Care Res (Hoboken). 2024 Feb;76(2):288-294. doi: 10.1002/acr.25222. Epub 2023 Oct 28.</mixed-citation><mixed-citation xml:lang="en">Nettleton E, Sattui SE, Wallace Z, Putman M. Incidence of Pneumocystis Jiroveci Pneumonia in Patients With ANCA-Associated Vasculitis Initiating Therapy With Rituximab or Cyclophosphamide. Arthritis Care Res (Hoboken). 2024 Feb;76(2):288-294. doi: 10.1002/acr.25222. Epub 2023 Oct 28.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Nakaya I, Sada KE, Harigai M, et al. Chemoprophylaxis against Pneumocystis jirovecii pneumonia in Japanese patients with ANCA-associated vasculitis: An observational study. Mod Rheumatol. 2023 Nov 1;33(6): 1137-1144. doi: 10.1093/mr/roac124.</mixed-citation><mixed-citation xml:lang="en">Nakaya I, Sada KE, Harigai M, et al. Chemoprophylaxis against Pneumocystis jirovecii pneumonia in Japanese patients with ANCA-associated vasculitis: An observational study. Mod Rheumatol. 2023 Nov 1;33(6): 1137-1144. doi: 10.1093/mr/roac124.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Haris A, Polner K, Aranyi J, et al. Simple, readily available clinical indices predict early and late mortality among patients with ANCA-associated vasculitis. BMC Nephrol. 2017 Feb 23;18(1):76. doi: 10.1186/s12882-017-0491-z.</mixed-citation><mixed-citation xml:lang="en">Haris A, Polner K, Aranyi J, et al. Simple, readily available clinical indices predict early and late mortality among patients with ANCA-associated vasculitis. BMC Nephrol. 2017 Feb 23;18(1):76. doi: 10.1186/s12882-017-0491-z.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Haris A, Polner K, Aranyi J, Braunitzer H, Kaszas I. Incidence and clinical predictors of infections in patients treated with severe systemic ANCA-associated vasculitis. Physiol Int. 2021 Mar 25. doi: 10.1556/2060.2021.00006. Online ahead of print.</mixed-citation><mixed-citation xml:lang="en">Haris A, Polner K, Aranyi J, Braunitzer H, Kaszas I. Incidence and clinical predictors of infections in patients treated with severe systemic ANCA-associated vasculitis. Physiol Int. 2021 Mar 25. doi: 10.1556/2060.2021.00006. Online ahead of print.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Odler B, Riedl R, Gauckler P, et al. Risk factors for serious infections in ANCA-associated vasculitis. Ann Rheum Dis. 2023 May;82(5):681-687. doi: 10.1136/ard-2022-223401. Epub 2023 Jan 26.</mixed-citation><mixed-citation xml:lang="en">Odler B, Riedl R, Gauckler P, et al. Risk factors for serious infections in ANCA-associated vasculitis. Ann Rheum Dis. 2023 May;82(5):681-687. doi: 10.1136/ard-2022-223401. Epub 2023 Jan 26.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Kronbichler A, Kerschbaum J, Gopalu ni S, et al. Trimethoprim-sulfamethoxazole prophylaxis prevents severe/life-threatening infections following rituximab in antineutro phil cytoplasm antibody-associated vasculitis. Ann Rheum Dis. 2018 Oct;77(10):1440-1447. doi: 10.1136/annrheumdis-2017-212861. Epub 2018 Jun 27.</mixed-citation><mixed-citation xml:lang="en">Kronbichler A, Kerschbaum J, Gopalu ni S, et al. Trimethoprim-sulfamethoxazole prophylaxis prevents severe/life-threatening infections following rituximab in antineutro phil cytoplasm antibody-associated vasculitis. Ann Rheum Dis. 2018 Oct;77(10):1440-1447. doi: 10.1136/annrheumdis-2017-212861. Epub 2018 Jun 27.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Kronbichler A, Jayne DR, Mayer G. Frequency, risk factors and prophylaxis of infection in ANCA-associated vasculitis. Eur J Clin Invest. 2015 Mar;45(3):346-68. doi: 10.1111/eci.12410</mixed-citation><mixed-citation xml:lang="en">Kronbichler A, Jayne DR, Mayer G. Frequency, risk factors and prophylaxis of infection in ANCA-associated vasculitis. Eur J Clin Invest. 2015 Mar;45(3):346-68. doi: 10.1111/eci.12410</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Charlier C, Henegar C, Launay O, et al. Risk factors for major infections in Wegener granulomatosis: analysis of 113 patients. Ann Rheum Dis. 2009 May;68(5):658-63. doi: 10.1136/ard.2008.088302. Epub 2008 May 26.</mixed-citation><mixed-citation xml:lang="en">Charlier C, Henegar C, Launay O, et al. Risk factors for major infections in Wegener granulomatosis: analysis of 113 patients. Ann Rheum Dis. 2009 May;68(5):658-63. doi: 10.1136/ard.2008.088302. Epub 2008 May 26.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">de Groot K, Harper L, Jayne DR, et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med. 2009 May 19; 150(10):670-80. doi: 10.7326/0003-4819-150-10-200905190-00004.</mixed-citation><mixed-citation xml:lang="en">de Groot K, Harper L, Jayne DR, et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med. 2009 May 19; 150(10):670-80. doi: 10.7326/0003-4819-150-10-200905190-00004.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Tesfa D, Ajeganova S, Hägglund H, et al. Late-onset neutropenia following rituximab therapy in rheumatic diseases: association with B lymphocyte depletion and infections. Arthritis Rheum. 2011 Aug;63(8):2209-14. doi: 10.1002/art.30427.</mixed-citation><mixed-citation xml:lang="en">Tesfa D, Ajeganova S, Hägglund H, et al. Late-onset neutropenia following rituximab therapy in rheumatic diseases: association with B lymphocyte depletion and infections. Arthritis Rheum. 2011 Aug;63(8):2209-14. doi: 10.1002/art.30427.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Harper L, Savage CO. ANCA-associated renal vasculitis at the end of the twentieth century – a disease of older patients. Rheumatology (Oxford). 2005 Apr;44(4):495-501. doi: 10.1093/rheumatology/keh522. Epub 2004 Dec 21.</mixed-citation><mixed-citation xml:lang="en">Harper L, Savage CO. ANCA-associated renal vasculitis at the end of the twentieth century – a disease of older patients. Rheumatology (Oxford). 2005 Apr;44(4):495-501. doi: 10.1093/rheumatology/keh522. Epub 2004 Dec 21.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Furuta S, Nakagomi D, Kobayashi Y, et al. Effect of Reduced-Dose vs High-Dose Glucocorticoids Added to Rituximab on Remission Induction in ANCA-Associated Vasculitis: A Randomized Clinical Trial. JAMA. 2021 Jun 1;325(21):2178-2187. doi: 10.1001/jama.2021.6615.</mixed-citation><mixed-citation xml:lang="en">Furuta S, Nakagomi D, Kobayashi Y, et al. Effect of Reduced-Dose vs High-Dose Glucocorticoids Added to Rituximab on Remission Induction in ANCA-Associated Vasculitis: A Randomized Clinical Trial. JAMA. 2021 Jun 1;325(21):2178-2187. doi: 10.1001/jama.2021.6615.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Walsh M, Merkel PA, Peh CA, et al. Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis. N Engl J Med. 2020 Feb 13;382(7):622-631. doi: 10.1056/NEJMoa1803537.</mixed-citation><mixed-citation xml:lang="en">Walsh M, Merkel PA, Peh CA, et al. Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis. N Engl J Med. 2020 Feb 13;382(7):622-631. doi: 10.1056/NEJMoa1803537.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Hellmich B, Sanchez-Alamo B, Schir mer JH, et al. EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update. Ann Rheum Dis. 2024 Jan 2; 83(1):30-47. doi: 10.1136/ard-2022-223764.</mixed-citation><mixed-citation xml:lang="en">Hellmich B, Sanchez-Alamo B, Schir mer JH, et al. EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update. Ann Rheum Dis. 2024 Jan 2; 83(1):30-47. doi: 10.1136/ard-2022-223764.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Захарова ЕВ, Буланов НМ. Клинические практические рекомендации KDIGO 2024 по ведению васкулита, ассоциированного с антителами к цитоплазме нейтрофилов (АНЦА). Нефрология и диализ. 2024;26(4):397-434.</mixed-citation><mixed-citation xml:lang="en">Zakharova EV, Bulanov NM. KDIGO 2024 Clinical Practice Guideline for the Management of Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis. Nefrologiya i dializ. 2024;26(4):397-434. (In Russ.).</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
